Rosacea

Rosacea is a chronic inflammatory skin disease that may be triggered by a number of factors (e.g., alcohol, stress). The etiology is unclear; however, the disease is more common in females and middle-aged individuals with fair skin. The disease presents with central facial erythema, telangiectasias, and papules/pustules. In severe cases, the nose develops a large, bulbous shape (rhinophyma). In contrast to acne, comedones are not present. Treatment options include the avoidance of triggers, topical agents (e.g., metronidazole, brimonidine) for mild disease and oral agents (e.g., metronidazole) for more severe disease.

• Sex: ♀ > ♂ ^[1]
• Age range: 30–60 years ^[1][2]

Epidemiological data refers to the US, unless otherwise specified.

The cause of rosacea is not entirely understood. It involves chronic inflammation of skin and is especially associated with triggers that increase body temperature.

• Trigger factors
  • Hot weather, hot drinks, spicy food
  • Stress, alcohol, nicotine
  • Demodex mites

References:^[1][3]

• Erythematotelangiectatic rosacea
  • Facial flushing
  • Persistent erythema of the face (together with telangiectasias)
• Papulopustular rosacea
  • Papules, pustules, and erythema
  • Comedones are not present in patients with rosacea.
• Phymatous rosacea
  • Skin and sebaceous glands thicken
  • Inflammatory, widespread nodules
  • Rhinophyma: enlarged, bulbous nose (almost exclusively in males)
  • Similar changes may occur on the chin, forehead, cheeks, and ears
• Ocular rosacea
  • Conjunctival hyperemia (most common)
  • Blepharitis (inflammation of the eyelid margin), stye (hordeolum externum), chalazion
  • Dry eyes and foreign-body sensation
  • Keratitis

In contrast to acne, comedones are NOT present in patients with rosacea.

References:^[4][5]

• Lifestyle modifications: avoid trigger factors (see "Etiology" above)
• Medical therapy
  • For erythema, flushing, skin sensitivity, xerosis:
    • Topical brimonidine
    • Topical oxymetazoline
  • For papules and pustules:
    • Topical agents for mild disease
      • Metronidazole (also for ocular rosacea)
      • Azelaic acid
      • Ivermectin
      • Sodium sulfacetamide
    • Oral agents for moderate to severe disease and refractory disease
      • Tetracyclines: e.g., doxycycline (also for ocular rosacea), tetracycline, minocycline
      • Isotretinoin (first-line for phymatous rosacea)
• Laser therapy: for erythema, telangiectasias, and phymatous rosacea
• Surgical therapy: for phymatous rosacea; includes electrocautery and dermabrasion

References:^[4][6][7][8]

1. Alinia H, Tuchayi SM, Patel NU, et al. Rosacea triggers. Dermatol Clin. 2018; 36 (2): p.123-126. doi: 10.1016/j.det.2017.11.007 . | Open in Read by QxMD
2. Rainer BM, Kang S, Chien AL. Rosacea: Epidemiology, pathogenesis, and treatment. Dermato-Endocrinology. 2017; 9 (1): p.e1361574. doi: 10.1080/19381980.2017.1361574 . | Open in Read by QxMD
3. Goldgar C, Keahey DJ, Houchins J. Treatment options for acne rosacea. Am Fam Physician. 2009; 80 (5): p.461-468.
4. Mikkelsen CS, Holmgren HR, Kjellman P, et al. Rosacea: a clinical review. Dermatol Reports. 2016; 8 (1). doi: 10.4081/dr.2016.6387 . | Open in Read by QxMD
5. Oge LK, Muncie HL, Phillips-Savoy AR. Rosacea: Diagnosis and treatment. Am Fam Physician. 2015; 92 (3): p.187-196.
6. Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. Clin Cosmet Investig Dermatol. 2015; 8 : p.159–177. doi: 10.2147/CCID.S58940 . | Open in Read by QxMD
7. Abokwidir M, Feldman SR. Rosacea Management. Skin Appendage Disord. 2016; 2 (1-2): p.26-34. doi: 10.1159/000446215 . | Open in Read by QxMD
8. Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018 . doi: 10.1111/bjd.16481 . | Open in Read by QxMD